BLASUBCUTANEOUSINJECTABLEPriority Review
Approved
Nov 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
Priority Review
NOVOLOG MIX 70/30 (insulin aspart) by Novo Nordisk. Approved for insulin analog [epc]. First approved in 2001.
Drug data last refreshed 7h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NOVOLOG MIX 70/30 is a premixed insulin analog combining 70% insulin aspart protamine suspension with 30% insulin aspart solution, administered subcutaneously. It is indicated for diabetes management in patients requiring both basal and bolus insulin coverage. The drug mimics the body's natural insulin secretion pattern by providing immediate and intermediate glucose control.
LOE Approaching
This product is in late-stage lifecycle with declining market exclusivity, signaling potential team consolidation and transition to cost-management and market-defense strategies.
Mechanism of Action
Pharmacologic Class:
Insulin Analog
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes
Started Aug 2025
877 enrolled
Diabetes Mellitus, Type 1
A Study of Insulin Degludec/Insulin Aspart Biosimilar (22011) Compared With Insulin Degludec/Insulin Aspart(Ryzodeg) in Participants With Type 2 Diabetes in China
Started Jul 2023
414 enrolled
Diabetes
A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)
Started Nov 2021
679 enrolled
Diabetes Mellitus, Type 2
A Study Investigating the Clinical Parameters Associated With the Use of Ryzodeg® (Insulin Degludec/Insulin Aspart) in a Real-world Adult Population With Type 2 Diabetes in South Korea
Started Apr 2021
200 enrolled
Diabetes Mellitus, Type 2
Comparison of Day and Night Closed-loop With Faster-acting Insulin Aspart With Insulin Aspart
Started Dec 2020
18 enrolled
Diabetes Mellitus, Type 1
Worked on NOVOLOG MIX 70/30 at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.